Company Description
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.
The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma.
In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11.
It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004.
Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2001 |
| IPO Date | Jun 26, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Steven A. Shallcross CPA |
Contact Details
Address: 9605 Medical Center Drive, Suite 270 Rockville, Maryland 20850 United States | |
| Phone | (734) 332-7800 |
| Website | therivabio.com |
Stock Details
| Ticker Symbol | TOVX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000894158 |
| ISIN Number | US87164U4094 |
| Employer ID | 13-3808303 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven A. Shallcross CPA | Chief Executive Officer, Chief Financial Officer, Treasurer, Corporate Secretary and Director |
| Dr. Vince Wacher Ph.D. | Head of Product and Corporate Development |
| Dr. Michael Kaleko M.D., Ph.D. | Senior Vice President of Research and Development |
| Dr. Ramon Alemany Ph.D. | Senior Vice President of Discovery and Chairman of Scientific Advisory Board |
| Lara M. Guzman | Senior Director of Project Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | 8-K | Current Report |
| Apr 22, 2024 | 8-K | Current Report |
| Apr 16, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 10-K | Annual Report |
| Mar 25, 2024 | 8-K | Current Report |
| Feb 7, 2024 | 8-K | Current Report |
| Jan 8, 2024 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 13, 2023 | 8-K | Current Report |
| Oct 23, 2023 | 8-K | Current Report |